1. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo
by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:
435-445.
2. Bar-Or A, Grove RA, Austin DJ, et al. Subcutaneous ofatumumab in
patients with relapsing-remitting multiple sclerosis: The MIRROR study.
Neurology 2018; 90: e1805-e1814.
3. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B
cell subsets after transient B cell depletion using anti-CD20 antibodies
in rheumatoid arthritis. Arthritis Rheum 2006; 54: 2377-2386.
4. Bemark M, Holmqvist J, Abrahamsson J, Mellgren K. Translational
Mini-Review Series on B cell subsets in disease. Reconstitution after
haematopoietic stem cell transplantation revelation of B cell
developmental pathways and lineage phenotypes. Clin Exp Immunol 2012;
167: 15-25.
5. Nissimov N, Hajiyeva Z, Torke S, et al. B cells reappear less mature
and more activated after their anti-CD20-mediated depletion in multiple
sclerosis. Proc Natl Acad Sci U S A. 2020; 117: 25690-25699.
6. Signoriello E, Bonavita S, Di Pietro A, et al. BMI influences CD20
kinetics in multiple sclerosis patients treated with
ocrelizumab. Mult Scler Relat Disord 2020); 43: 102186.
7. Leandro MJ. B-cell subpopulations in humans and their differential
susceptibility to depletion with anti-CD20 monoclonal antibodies.
Arthritis Res Ther 2013; 15 (Suppl 1): S3.
8. Baker D, Roberts CAK, Pryce G, et al. Covid 19 vaccine readiness for
anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol
2020; 202: 149-161.